CANbridge Pharmaceuticals Inc. (01228)
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
